Welcome to our dedicated page for Fresenius Med Cr SEC filings (Ticker: FMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fresenius Medical Care AG's SEC filings document its reporting as a German foreign private issuer with ordinary shares and ADRs listed in Frankfurt and New York. Form 6-K reports furnish quarterly and full-year results, press releases, IFRS financial figures, non-GAAP reconciliations, share buyback disclosures, and material updates affecting the company's kidney care operations.
The filing record also covers the Form 20-F annual report, audited consolidated financial statements, Annual General Meeting materials, ADR voting instruction cards, compensation reporting, Supervisory Board reports, and Management Board explanatory reports under German corporate law. Segment disclosures identify Care Delivery, Care Enablement, Value-Based Care, health care services, and health care products.
Fresenius Medical Care AG reports interim operating updates and segment changes. As of June 1, 2025, the company created a new Value‑Based Care segment, recognizing full‑risk arrangements under IFRS 17 with premiums and claim costs presented separately. For the nine months ended September 30, 2025, 16% of consolidated revenue was attributable to U.S. federally funded programs.
Capital efficiency remained modest: ROIC was 4.1%, or 4.9% excluding Legacy Portfolio Optimization costs, based on NOPAT of €1,101 M and average invested capital of €27,150 M. Total assets were €30,887 M and invested capital €25,471 M as of September 30, 2025.
Regulatory dynamics continue to influence U.S. operations. CMS proposed to terminate the mandatory ETC model on December 31, 2025; 971 U.S. facilities (about 35%) are currently in ETC regions and the program to date produced a net positive payment adjustment. The company participates in 21 KCEs, with approximately 52,000 patients aligned as of September 2025, reflecting scale in value‑based kidney care.
Fresenius Medical Care AG furnished a Form 6-K announcing its third quarter results for the period ended September 30, 2025. The submission includes a press release (Exhibit 99.1) and accompanying financial figures (Exhibit 99.2).
The company highlights non-GAAP measures alongside IFRS results, including EBITDA, free cash flow, net leverage ratio (net debt to adjusted EBITDA), constant-currency metrics, and results adjusted for special items, with reconciliations provided in the exhibits. The exhibits are furnished, not filed.